The University of Michigan Comprehensive Cancer Center (UMCCC) requests renewal of its core grant in support of Senior Leadership, Programs, and Shared Core Facilities. A core grant to support the UMCCC was initially awarded by the NCI in 1988, with continuous funding since then. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of defined clinical, basic, and prevention programs in cancer research and the development of shared core resources. In 1997 the Center moved into a new $88 million facility which houses the Center's outpatient clinics as well as many of its research laboratories. The Cancer Center has continued to experience considerable growth over this grant period with 70 new faculty recruited and an 85% increase in NCI funding. The Cancer Center's 13 research programs include the basic research programs in Cancer Genetics, Cancer Cell Biology, Molecular Therapeutics, Radiation Sciences, and Molecular Imaging. Clinical research programs include Prostate/Urological, Breast, Leukemia/Lymphoma-BMT, Gl, Childhood Cancers, and Head &Neck cancers. The prevention programs include two programs: Biomedical Prevention and Socio-Behavioral. Support is requested for a total of 16 shared core facilities. These include Clinical Trials, Biostatistics, Tissue Procurement, Tumor Imaging, DNA Sequencing, Morphology, Flow Cytometry, Experimental Irradiation, Animal Facility, Transgenic Mouse, Vector Core, Immune Monitoring, cDNA Affymetrix and Microarray and three new cores including Proteomics, Bioinformatics, and Health Communications. Funds are also requested for development, planning and evaluation, and administration to support Center goals. The Medical Center has made substantial commitments to the Cancer Center of approximately $175 million. Its 285 UMCCC members receive over $82 million in research funding, including over $37 million in annual direct NCI support. The UMCCC has had a major impact on cancer research as evidenced by publishing at least 315 articles in high impact journals, placing 52% of UMCCC intervention accruals onto investigator-initiated trials and consistently ranking among the top ten Cancer Centers nationally for NCI funding over this grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046592-23S1
Application #
8145378
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-06-01
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2012-05-31
Support Year
23
Fiscal Year
2010
Total Cost
$100,000
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Feinberg, Tamar Y; Zheng, Huarui; Liu, Rui et al. (2018) Divergent Matrix-Remodeling Strategies Distinguish Developmental from Neoplastic Mammary Epithelial Cell Invasion Programs. Dev Cell 47:145-160.e6
Boonstra, Philip S; Barbaro, Ryan P (2018) Incorporating historical models with adaptive Bayesian updates. Biostatistics :
Johnson, Allison M; Roach, James P; Hu, Anna et al. (2018) Connexin 43 gap junctions contribute to brain endothelial barrier hyperpermeability in familial cerebral cavernous malformations type III by modulating tight junction structure. FASEB J 32:2615-2629
Sucularli, Ceren; Thomas, Peedikayil; Kocak, Hande et al. (2018) High-throughput gene expression analysis identifies p53-dependent and -independent pathways contributing to the adrenocortical dysplasia (acd) phenotype. Gene 679:219-231
Hrycaj, Steven M; Marty-Santos, Leilani; Cebrian, Cristina et al. (2018) Hox5 genes direct elastin network formation during alveologenesis by regulating myofibroblast adhesion. Proc Natl Acad Sci U S A 115:E10605-E10614
Subramanian, Chitra; Grogan, Patrick T; Opipari, Valerie P et al. (2018) Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-?B activation. Oncotarget 9:14509-14523
Wang, Qing; Yan, Ran; Pinnell, Nancy et al. (2018) Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development. Blood 132:1279-1292
Owen, Daniel Rocky; Boonstra, Phillip S; Viglianti, Benjamin L et al. (2018) Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage. Int J Radiat Oncol Biol Phys 102:1265-1275
Dame, Michael K; Attili, Durga; McClintock, Shannon D et al. (2018) Identification, isolation and characterization of human LGR5-positive colon adenoma cells. Development 145:
Abel, Ethan V; Goto, Masashi; Magnuson, Brian et al. (2018) HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife 7:

Showing the most recent 10 out of 1493 publications